Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 11, 2019 3:05 AM 3 min read

Premier Health Announces International Medical Cannabis Expansion Strategy

by Globe Newswire
Follow

VANCOUVER, British Columbia, April 11, 2019 (GLOBE NEWSWIRE) -- Premier Health Group Inc. (CSE:PHGI, OTCQB:PHGRF, Frankfurt: 6PH))) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is pleased to announce the launch of an international expansion strategy to broaden its reach through its medical cannabis initiatives. As more countries legalize medical cannabis, Premier Health will be focusing on selling its comprehensive Electronic Medical Record (EMR) platform with medical cannabis software integration for education, decision support, and the prescription of medical cannabis to fast-growing markets in countries such as the US, the UK and Australia.

The legalization of medical cannabis is projected to boost the demand for cannabis for medical use as a substitute for traditional medicines. Approximately 30 countries have already legalized medical cannabis in some capacity, as well as a small handful of others that allow its use within strict guidelines, such as in the form of cannabis-derived pharmaceuticals. According to a report by Zion Market Research, the global medical cannabis market was valued at approximately USD $11.8 billion in 2017 and is expected to generate revenue of around USD $40.9 billion by the end of 2024. In addition, according to P&S Market Research, the global EMR market is projected to attain a size of $30.4 billion by 2023.

The role of cannabis in treating medical conditions is continuously expanding to help patients with acute and chronic symptoms. Currently, there is a critical gap between the patient's need for medical cannabis, and the physician's comfort and knowledge to prescribe it. This knowledge gap is even more widespread in countries that are behind Canada in its adoption of medical cannabis. In addition, research into the safety and efficacy of cannabis has traditionally been very difficult. Premier Health is looking to fill that gap by using clinically led, evidence-based data which will be embedded directly in the Company's EMR software to help guide doctors to the appropriate medical cannabis product and dosing. The software will be further tailored to the regulatory and approval procedures associated with the different jurisdictions.

"With the increasing awareness and demand from patients around the use of medical cannabis, we are aiming to provide the best possible information and appropriate tools to physicians so they can make informed decisions about their patients' health," said Dr. Essam Hamza, CEO of Premier Health. "As a pioneer in the space, Canada is at the forefront of this changing landscape. Our focus will be to bring credible physician-backed cannabis education to primary care physicians, where knowing your patient is an essential element of practice. Additionally, by innovating and integrating these increasingly in demand capabilities, Premier Health will be equipped to significantly increase its market share of the $30 billion EMR market."

In order to gain traction in various jurisdictions, the Company will be leveraging existing global relationships and will provide further updates in Q3-19.

ON BEHALF OF THE BOARD OF DIRECTORS

"Dr. Essam Hamza, MD"
Chief Executive Officer

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. Premier Health, in conjunction with its subsidiary Cloud Practice, a cloud-based SAAS Electronic Medical Records software company, is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have a combined ecosystem of 290 clinics, over 3000 licensed practitioners and almost 3 million registered patients. The Premier Health team has deep clinical, operational and financial expertise and a passion for improving healthcare for all patients.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

FOR ADDITIONAL INFORMATION CONTACT:

Premier Health Group Inc.
www.mypremierhealth.com
Email: [email protected]

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Press Releases
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...